Pioneering the Future of Regenerative Medicine

Wound Care

CDH is working on healing of chronic and acute wounds, successfully developing and testing products for diabetic chronic wounds and bedsores (pressure ulcers).

We developed a chronic wound formulation, D-Qure, using selective herbal exosomes (EVs) in a liquid spray format. The same is currently tested for bedsores, though we are working on a unique formulation for this condition, D-Qure has proven efficacious for this condition as well.

Acute wounds: the difficulty of open cuts on general wounds is that they will attract bacterial infection faster when exposed. CDH addressess open wounds, immediately drying the top layer, bridging the tissues to close the wound rapidly, within two to three days.

Eczema

Autoimmune diseases have a reduced chance of complete curing, however CDH has developed an eczema cream, reducing symptoms and helping reduce bacterial spread across the affected area. This action helps quickly reduce concommitant symptoms such as itchiness, dryness, and rashes.

CDH is also working on pediatric eczema, by using its properiatary formulation technology to selectively target this condition in children.

AMD and Eye Care

We are working on Dry AMD eye drops as a supplement and OTC product for early-stage AMD, as a first-line support mechanism.

In parallel, other research includes products for double vision issues in adults with mild to significant double vision reduction. The formulations include a slow-release gel and fast-acting drops. We believe these products may address colour corrections, and overlapping image sensor corrections.

Additionally, we are working on early-stage Myopia, using proprietary plant-based exosomes combined with a proprietary peptide regulator for eye elongation.